Xeris Biopharma Holdings Inc XERS Fundamentals and Key Ratios

Xeris Biopharma Holdings Inc. (XERS) Fundamentals


Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

SHARE INFORMATION
Market Cap	$ 182,593,841
Shares Outstanding	137,288,602
Float	122,828,787
Percent Float	89.47%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 110,248,000
Latest Fiscal EPS	$ -0.70
Latest Fiscal Date	2022-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	219
Institutional Holdings Date	2023-02-28
Institutional Bought Previous 3 Months	1,888,378
Institutional Holdings Percent	61.9%
Institutional Sold Previous 3 Months	2,881,969
Insider Holdings Date	2023-02-28
Insider Bought Previous 3 Months	2,870,000
Insider Holdings Percent	5.5
Insider Sold Previous 3 Months	-
Insider Shares Owned	7,489,712

TRADING INFO
52 Week High	$ 2.85
52 Week Low	$ 0.97
52 Week High Change	$ -50.56
21 Day Moving Average	$ 1.3305
21 Day Extended Moving Average	$ 1.3018
50 Day Moving Average	$ 1.2656
50 Day Extended Moving Average	$ 1.291
200 Day Moving Average	$ 1.458
200 Day Extended Moving Average	$ 1.5321
10 Day Average Volume	669,330
20 Day Average Volume	1,075,281
30 Day Average Volume	1,104,390
50 Day Average Volume	945,678
Alpha	-0.026956
Beta	1.3007
Standard Deviation	0.252983
R2	0.081545
7 Day Price Change	$ -0.01
7 Day Percent Change	-0.75%
21 Day Price Change	$ -0.20
21 Day Percent Change	-13.07%
30 Day Price Change	$ -0.05
30 Day Percent Change	-3.62%
Month to Date Price Change	$ -0.05
Month to Date Percent Change	-3.62%
Quarter to Date Price Change	$ 0.00
Quarter to Date Percent Change	0.0%
180 Day Price Change	$ -0.25
180 Day Percent Change	-15.82%
200 Day Price Change	$ -0.49
200 Day Percent Change	-26.92%
Year to Date Price Change	$ 0.00
Year to Date Percent Change	0.0%

PROFITABILITY
EBIT Margin	-122.7%
EBITDA Margin	-112.4%
Pre-Tax Profit Margin	-1,567.1%
Profit Margin Count	-83.82%
Gross Margin	79.5%
Profit Margin TOT	-83.82%

INCOME STATEMENTS
Revenue	$ 110,248,000
Revenue Per Share	$ 0.803
Revenue (3 Years)	$ 231.75
Revenue (5 Years)	$ 151.85

FINANCIAL STRENGTH
Price to Tangible Book	-1.80
Total Debt To Equity	4.40
Int Coverage	-5.30
Current Ratio	2.50
Leverage Ratio	4.80
Quick Ratio	2.10
Long Term Debt To Capital	0.81

VALUATION MEASURES
PE Ratio	20.00
Enterprise Value	$ 251,820,410
Price to Sales	1.6562
Price to Free Cash	-1.70
PE High Last 5 Years	-1.50
Price To Book	3.90
Price To Cash Flow	0.00
PE Low Last 5 Years	-1.20
Price to Tangible Book	-1.80

MANAGEMENT EFFECTIVENESS
Receivables Turnover	4.50
Invoice Turnover	1.00
Assets Turnover	0.30
Return Assets	-29.97
Return on Equity	-140.22
Return on Capital	-86.56

PROFILE INFO
Issue Type	CS
SEC Type	-
Auditor	KPMG LLP
CEO	Paul R. Edick
Emplyoees	294
Last Audit	UE
CIK	0001867096
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)

CONTACT INFO
Address	180 North LaSalle Street Suite 1600 Chicago, IL 60601
Website	https://www.xerispharma.com
Facsimile	-
Telephone	+1 844 445-5704
Email	awey@xerispharma.com

Boards:

Quotes:

XERS